Major cancer trial tests new drug combo against standard treatment
NCT ID NCT06591520
Summary
This large Phase 3 study compares two different immunotherapy combinations for people with advanced bile duct cancer that cannot be removed by surgery. Researchers are testing whether a new drug called AK112 works better than the established drug durvalumab when both are given with standard chemotherapy. The study aims to see which combination helps patients live longer and better controls the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Harbin Medical University Cancer Hospital
Harbin, China
-
Zhongshan Hospital, Fudan University
Shanghai, China
Conditions
Explore the condition pages connected to this study.